2 recruiting, 1 completed, 1 terminated, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow PepGen Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) PGN-EDODM1 - Myotonic Dystrophy 1 | Phase 2 | Recruiting | PepGen Inc | 48 | 2025-12-23 | 2026-03-30 |
| A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment IV infusion, Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Withdrawn | PepGen Inc | 2024-12-17 | 2025-06-24 | |
| A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 PGN-EDODM1, Placebo - Myotonic Dystrophy 1 | Phase 2 | Recruiting | PepGen Inc | 24 | 2024-12-10 | 2026-07-29 |
| A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment PGN-EDO51 - Duchenne Muscular Dystrophy | Phase 2 | Terminated | PepGen Inc | 7 | 2024-01-03 | 2025-12-02 |
| Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 PGN-EDODM1 for infusion, Placebo - Myotonic Dystrophy 1 | Phase 1 | Completed | PepGen Inc | 24 | 2023-12-12 | 2026-02-13 |
Neuromuscular Diseases (4) · Muscular Dystrophies (3) · Myotonic Dystrophy (3) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Muscular Diseases (2) · Muscular Disorders, Atrophic (2) · Muscular Dystrophy, Duchenne (2) · Musculoskeletal Diseases (2) · Myotonic Disorders (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (1)
Canada (4) · United Kingdom (2) · New Zealand (1) · South Korea (1) · United States (1)
2023 (1)